Nine-Year Survival Outcome Of Neoadjuvant Lapatinib With Trastuzumab For Her2-Positive Breast Cancer (Neoaltto, Big 1-06): Final Analysis Of A Multicentre, Open-Label, Phase 3 Randomised Clinical Trial.
EUROPEAN JOURNAL OF CANCER（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要